What is the 13F Pro Quality Score for SNGX?

13F Pro ranks SOLIGENIX, INC. (SNGX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SNGX's current score at https://13fpro.ai/research/SNGX (free sign-up required for the full ranking).

Where does 13F Pro source SNGX data?

All SOLIGENIX, INC. fundamentals and ownership data come directly from SEC EDGAR. SOLIGENIX, INC. files with the SEC under CIK 812796. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SNGX in?

SOLIGENIX, INC. (SNGX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is SNGX research updated on 13F Pro?

SNGX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

SOLIGENIX, INC.(SNGX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 812796 SNGX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $10.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

SNGX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for SOLIGENIX, INC. (SNGX), a Healthcare sector company. SNGX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $10.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), SOLIGENIX, INC. reports net income of $-2.8M, free cash flow of $-2.4M. Top institutional holders of SNGX by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. SNGX trades on the Nasdaq exchange and files with the SEC under CIK 812796. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SNGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SOLIGENIX, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-2.8M

Free Cash Flow

Q1 2026

$-2.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 $948.9KFY23 $839.4KFY24 $119.4KFY25 —

Net Income

-34.0% YoY

$-11.1MFY 2025

FY22 $-13.8MFY23 $-6.1MFY24 $-8.3MFY25 $-11.1M

Operating Income

-25.5% YoY

$-11.8MFY 2025

FY22 $-14.2MFY23 $-7.7MFY24 $-9.4MFY25 $-11.8M

EPS (Diluted)

+57.0% YoY

$-2.14FY 2025

FY22 $-4.81FY23 $-12.66FY24 $-4.98FY25 $-2.14

Total Assets

+3.0% YoY

$9.2MFY 2025

FY22 $14.3MFY23 $9.8MFY24 $9.0MFY25 $9.2M

Total Debt

—FY 2025

FY22 $0.00FY23 $1.0MFY24 $0.00FY25 —

Op. Cash Flow

-22.2% YoY

$-10.3MFY 2025

FY22 $-12.6MFY23 $-8.6MFY24 $-8.4MFY25 $-10.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	$119.4K -85.8%	$839.4K -11.5%	$948.9K +15.1%	$824.3K -65.1%	$2.4M
Net Income	$-11.1M -34.0%	$-8.3M -34.6%	$-6.1M +55.5%	$-13.8M -9.9%	$-12.6M +29.0%	$-17.7M
Operating Income	$-11.8M -25.5%	$-9.4M -22.6%	$-7.7M +45.9%	$-14.2M -8.7%	$-13.1M +29.5%	$-18.6M
EPS (Diluted)	$-2.14 +57.0%	$-4.98 +60.7%	$-12.66 -163.2%	$-4.81 -2.6%	$-4.69 -632.8%	$-0.64
Total Assets	$9.2M +3.0%	$9.0M -8.5%	$9.8M -31.4%	$14.3M -46.9%	$26.9M +35.1%	$19.9M
Total Debt	—	$0.00 -100.0%	$1.0M	$0.00	—	—
Operating Cash Flow	$-10.3M -22.2%	$-8.4M +2.3%	$-8.6M +32.0%	$-12.6M -7.7%	$-11.7M -2.5%	$-11.5M

AI Insight: SNGX Financial Trends

SNGX remains pre-revenue across all eight reported quarters, burning $2–3M cash per quarter with no inflection visible.

• Revenue has been $0M every quarter from Q2 2024 through Q4 2025, with Q1 2026 unreported — no commercial progress evident.

• Operating cash outflow has held steady at $-2M to $-3M per quarter, suggesting no meaningful acceleration or reduction in burn rate.

• Equity swung from $3M in Q2 2024 to $8M in Q3 2025 then fell to $3M in Q1 2026, reflecting episodic dilutive raises offsetting losses.

⚠ Equity compressed to $3M in Q1 2026 — near the lowest level in the dataset — raising near-term financing risk.

⚠ Total debt data is missing from Q1 2025 onward; debt obligations and covenant status are unverifiable from available figures.

AI Insight: SNGX Ratio Trends

Sparse data reveals only deeply negative returns on equity and assets, confirming SNGX remains a pre-revenue clinical-stage burner with limited measurable financial trends.

• ROE improved from -189.8% in Q2 2024 to -115.9% in Q3 2024, then deteriorated to -133.2% in Q3 2025.

• ROA held deeply negative: -66.7% in Q2 2024, -65.6% in Q3 2024, worsening to -89.6% in Q3 2025.

• D/E declined from 0.29 in Q2 2024 to 0.00 in Q4 2024, suggesting debt was fully retired or converted.

⚠ Most ratio fields — OpMargin, NPM, ROIC — are entirely absent, making trend analysis unreliable.

⚠ ROA worsening to -89.6% in Q3 2025 signals accelerating asset erosion; cash runway is the key risk.

Get alerted when SNGX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for SOLIGENIX, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SNGX

GEODE CAPITAL MANAGEMENT, LLC
$141.9K120,267 sh
VANGUARD CAPITAL MANAGEMENT LLC
$68.9K58,400 sh
VANGUARD FIDUCIARY TRUST CO
$63.6K53,914 sh
XTX Topco Ltd
$24.5K20,799 sh
MORGAN STANLEY
$4.2K3,592 sh
UBS Group AG
$2.8K2,346 sh
SBI Securities Co., Ltd.
$474.00402 sh
Advisory Services Network, LLC
$247.00209 sh
Plante Moran Financial Advisors, LLC
$247.00209 sh
JONES FINANCIAL COMPANIES LLLP
$113.00100 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$141.9K	120,267
VANGUARD CAPITAL MANAGEMENT LLC	$68.9K	58,400
VANGUARD FIDUCIARY TRUST CO	$63.6K	53,914
XTX Topco Ltd	$24.5K	20,799
MORGAN STANLEY	$4.2K	3,592
UBS Group AG	$2.8K	2,346
SBI Securities Co., Ltd.	$474.00	402
Advisory Services Network, LLC	$247.00	209
Plante Moran Financial Advisors, LLC	$247.00	209
JONES FINANCIAL COMPANIES LLLP	$113.00	100

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SNGX on your watchlist

Track score changes the day SOLIGENIX, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SNGX a good stock to buy?

13F Pro's AI-powered analysis of SOLIGENIX, INC. (SNGX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SNGX are available on the SNGX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own SNGX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SNGX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of SOLIGENIX, INC.'s investment landscape.